Abstract
Transformed cells suffer several changes leading to the increase of protective mechanisms and show a metabolic profile in accordance with higher proliferative capacity. In these mechanisms, changes in mitochondrial activity cause a higher glycolytic metabolism in detriment of oxidative phosphorylation. In these changes, H+-ATPase regulation seems to be importantly involved. During the last years, polyphenols and specially the stilbene resveratrol and related members of its family have been studied because they are able to affect tumour cell growth and cancer progression. Among the different effects induced by resveratrol, inhibition of H+-ATPase seems to be one important mechanism in its effect on cancer progression. Further, an ectopic H+-ATPase located in the outer surface of plasma membrane has been recently involved in cancer progression and angiogenesis. In this article we review the latest findings about resveratrol inhibition of H+-ATPase and its importance in tumour cell growth and cancer progression.
Keywords: Resveratrol, polyphenols, H+-ATPase, mitochondria, angiogenesis, cell growth, transformed cells, glycolytic metabolism, oxidative phosphorylation, cancer progression
Current Pharmaceutical Design
Title: Resveratrol in Cancer: Cellular and Mitochondrial Consequences of Proton Transport Inhibition
Volume: 18 Issue: 10
Author(s): Guillermo Lopez-Lluch, Sara Santa Cruz-Calvo and Placido Navas
Affiliation:
Keywords: Resveratrol, polyphenols, H+-ATPase, mitochondria, angiogenesis, cell growth, transformed cells, glycolytic metabolism, oxidative phosphorylation, cancer progression
Abstract: Transformed cells suffer several changes leading to the increase of protective mechanisms and show a metabolic profile in accordance with higher proliferative capacity. In these mechanisms, changes in mitochondrial activity cause a higher glycolytic metabolism in detriment of oxidative phosphorylation. In these changes, H+-ATPase regulation seems to be importantly involved. During the last years, polyphenols and specially the stilbene resveratrol and related members of its family have been studied because they are able to affect tumour cell growth and cancer progression. Among the different effects induced by resveratrol, inhibition of H+-ATPase seems to be one important mechanism in its effect on cancer progression. Further, an ectopic H+-ATPase located in the outer surface of plasma membrane has been recently involved in cancer progression and angiogenesis. In this article we review the latest findings about resveratrol inhibition of H+-ATPase and its importance in tumour cell growth and cancer progression.
Export Options
About this article
Cite this article as:
Lopez-Lluch Guillermo, Santa Cruz-Calvo Sara and Navas Placido, Resveratrol in Cancer: Cellular and Mitochondrial Consequences of Proton Transport Inhibition, Current Pharmaceutical Design 2012; 18 (10) . https://dx.doi.org/10.2174/138161212799504849
DOI https://dx.doi.org/10.2174/138161212799504849 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cytotoxic and Radio-sensitizing Effects of Polyphenolic Acetates in a Human Glioma Cell Line (BMG-1)
Current Pharmaceutical Design Nifurtimox Hampered the Progression of Astroglioma <i>In vivo Via</i> Manipulating the AKT-GSK3β axis
Current Molecular Medicine Combinatorial Nanoparticles for Cancer Diagnosis and Therapy
Current Medicinal Chemistry Specific Targeting of Akt Kinase Isoforms: Taking the Precise Path for Prevention and Treatment of Cancer
Current Drug Targets Antibody-Onconase Conjugates: Cytotoxicity and Intracellular Routing
Current Pharmaceutical Biotechnology Nanoparticle Coated Viral Vectors for Gene Therapy
Current Biotechnology Identifying S100B as a Biomarker and a Therapeutic Target For Brain Injury and Multiple Diseases
Current Medicinal Chemistry Potential Usage of ING Family Members in Cancer Diagnostics and Molecular Therapy
Current Drug Targets Regulatable Gene Expression Systems for Gene Therapy
Current Gene Therapy Endogenous Regulators of Adult CNS Neurogenesis
Current Pharmaceutical Design ADAM8/MS2/CD156, an Emerging Drug Target in the Treatment of Inflammatory and Invasive Pathologies
Current Pharmaceutical Design Progress of HDAC Inhibitor Panobinostat in the Treatment of Cancer
Current Drug Targets Recent Advances in Antabuse (Disulfiram): The Importance of its Metal-binding Ability to its Anticancer Activity
Current Medicinal Chemistry State of Research Tracks and Property Protection of Photodynamic Sensitizers and Delivery Methodologies
Recent Patents on Chemical Engineering Gene Therapy: The First Approved Gene-Based Medicines, Molecular Mechanisms and Clinical Indications
Current Molecular Pharmacology The Radiosensitizing Effect of Olanzapine as an Antipsychotic Medication on Glioblastoma Cell
Current Radiopharmaceuticals Evasion of Ribonuclease Inhibitor as a Determinant of Ribonuclease Cytotoxicity
Current Pharmaceutical Biotechnology Mitochondria-Targeting Anticancer Metal Complexes
Current Medicinal Chemistry Interferons: Mechanisms, Biological Activities and Survey of their Use in Human Diseases
Current Bioactive Compounds Fluorescence-Guided Malignant Glioma Resections
Current Drug Discovery Technologies